Join Dr. Raymond A. Huml, Vice President of Rare Strategy, Sciensus; Andrew Cummins, Vice President of Business Development, Sciensus; and Kirsty Hoyle, CEO, Metabolic Support UK, for the live webinar ...

PTC Therapeutics could boost revenue with vatiquinone for Friedreich's ataxia. Find out why PTCT stock is poised for growth ...

While the IRA architects were building their anti-innovation government drug pricing plan, they also included a provision to ...

The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Plus Therapeutics’ injectable ...

Small-Cap Firms Dominate Market Rally. In this article, we are going to take a look at where Plus Therapeutics, Inc.

The FDA granted orphan drug status to rhenium-186 obisbemeda for treating leptomeningeal metastases in lung cancer.

Shares of Plus Therapeutics, Inc. PSTV were up a whopping 311.4% on March 6 after the company announced that the FDA has ...

ENCell’s investigational drug EN001 has been granted Orphan Drug Designation by the FDA for the treatment of ...

Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Features of Systemic Sclerosis. TEL AVIV, Israel, (GLOBE NEWSWIRE) -- C ...

Plus Therapeutics (PSTV) soars with FDA's Orphan Drug Designation for Rhenium Obisbemeda, targeting rare leptomeningeal metastases.

The United States Cutaneous Lymphoma Consortium is a multidisciplinary society of physicians which use collaborative research and education to improve the quality of life and prognosis of patients ...

Plus Therapeutics (PSTV) announces that the U.S. Food and Drug Administration has granted Orphan Drug Designation to Rhenium Obisbemeda for the ...